In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates

By K. Musunuru, A. Chadwick, Taiji Mizoguchi, Sara P. Garcia, J. Denizio, C. Reiss, Kui Wang, Sowmya Iyer, C. Dutta, V. Clendaniel and 32 more. Nature, 2021

676 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Molecular Biology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/a6a4899a2d1e3593fdf9c70f08d939b94ebc6979

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Jennifer A. Doudna

In Molecular Biology

1. Joy Y. Wang
2. Jennifer A. Doudna
3. Feng Zhang
4. Lei S. Qi
5. Rodolphe Barrangou

In Public Health, Environmental and Occupational Health

1. Jennifer A. Doudna

Citations in the corpus

• CRISPR technology: A decade of genome editing is only the beginning (2023, methodology): “For example, as safety and efficacy are established for disease treatment, genome editing might become a prophylactic against neurodegenerative or cardiovascular disease (31).”